Research on the Use of Probiotics in the Prevention and Treatment of Inflammatory Bowel Disease
NCT ID: NCT06781827
Last Updated: 2025-04-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
50 participants
INTERVENTIONAL
2025-01-01
2025-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Two Probiotic Products on the Intestinal Barrier Function in Patients With Irritable Bowel Syndrome
NCT03986476
Efficacy of Probiotics in Patients With IBD
NCT05652621
Multi Strain Probiotic Preparation in Patients With Irritable Bowel Syndrome
NCT04662957
Nutrition to Relieve IBS Symptoms by Targeting the Microbiota
NCT04790422
Modulation of Intestinal Barrier Function and Inflammation Via Butyrate-promoting Dietary Fibre
NCT05058131
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotic
Daily intervention with Limosilactobacillus reuteri LR08 (10 billion CFU, 2g) for 8 weeks, stored in a cool and dry place.
Probiotic
The experimental phase of the study lasts 8 weeks and each patient will be visited 4 times (January, March, June, and December).
Placebo
Every day to give 3 g maltodextrin intervention for 8 weeks. Store in a cool and dry place.
Maltodextrin
The experimental phase of this study had last 8 weeks and each patient will make 4 visits (January, March, June, and December).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic
The experimental phase of the study lasts 8 weeks and each patient will be visited 4 times (January, March, June, and December).
Maltodextrin
The experimental phase of this study had last 8 weeks and each patient will make 4 visits (January, March, June, and December).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Agree to sign informed consent; Have been diagnosed with IBD for at least 3 months but not more than 3 years -
Exclusion Criteria
2. Patients with other autoimmune diseases, infectious diseases and malignant tumors Patients with CD during pregnancy and lactation; Patients with serious diseases of the liver, kidney, heart and lung, etc
3. Patients with allergic diseases such as asthma and allergic rhinitis; alcoholic Patients with mental illness
4. Patients with suspected cancer in their intestines
5. Antibiotics, probiotics and prebiotics have been used in the past three months Had intestinal surgery (except appendicitis surgery)
6. There is currently an infection
7. He has had cancer in the last 5 years -
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wecare Probiotics Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gastroenterology Department of Jiangsu Province （Suqian）Hospital
Suqian, Jiangsu, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WK20250106
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.